Adenosine vs Diltiazem for Treatment of SVT in the ED

Conditions

• Supraventricular Tachycardia (SVT)

Eligibility Criteria

Sex

ALL

Age

18 Years - 100 Years

Healthy Volunteers

Not accepted

Interventions

• adenosine — DRUG
  IV adenosine at standard doses for SVT (6 mg, 12 mg)
• diltiazem — DRUG
  IV diltiazem at standard doses for SVT (0.25 mg/kg)

Study Details

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Key Dates

Start date

Aug 1, 2025

Status verified

May 2026

Primary completion

Jul 31, 2027

Completion

Dec 31, 2027

Study Design

Enrollment

20 participants (estimated)

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Active Comparator: Adenosine
• Active Comparator: Diltiazem

Primary Outcome Measure

Feasibility outcome [ Time Frame: From enrollment to the end of ED encounter (up to 24 hours). ]

Central Contacts

• Anne Zepeski, PharmD
  (319) 356-2577
  [email protected]

Locations (1)

Find similar trials in Iowa City, IA

Related Studies

• PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency Department
  Recruiting · University of Iowa · Iowa City, Iowa